Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2~* Unilateral upper limb secondary lymphedema~* Must have the ability to understand and the willingness to sign a written informed consent document~* Must agree to blood serum assessment including, complete blood count (CBC) with differential; comprehensive metabolic panel and serum osmolality at every sanctioned evaluation; additionally physician may require cardiac evaluation with echocardiogram, electrocardiogram, brain natriuretic peptide or urinalysis if deemed appropriate~* Must consent to multi-bio-frequency impedance analysis (MFBIA); the details are to be covered in consent~* Willing to sign consent for skin biopsies and phlebotomy~* Women of child bearing potential must have a documented negative pregnancy test within 2 weeks prior to day 1 of treatment and agree to use a non-hormonal form of birth control during the duration of the trial therapy~Exclusion Criteria:~* Pregnant or actively breast-feeding~* Bilateral upper extremity edema~* Bilateral manipulation of axilla within the last 24 months~* Active infections~* Receiving concomitant treatment for upper extremity lymphedema, or who have received treatment within the last 14 days~* Known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extracts~* Receiving concomitant diuretics or dihydropyridine class of calcium channel blockers; if an alternative medication is available, patient can become eligible after 3 half-lives of drug discontinued and patient remains medically stable~* Grade 2 or greater hypo-albuminemia, serum sodium greater than 150meq/L, serum osmolality greater than 300mOsm/kg or blood urea nitrate/serum creatinine ratio greater than 25, within 7 days of screening~* Unable or unwilling to self/home administer subcutaneous experimental drug; study nurse or physician will train individuals on proper administration techniques~* Unwilling or incapable of maintaining a detailed log of number of injections, the date, time and site of administration~* Active malignancy; those undergoing active treatment for malignancy in the adjuvant setting are eligible; treatment can include chemotherapy, targeted therapy or anti-hormonal therapy~* At least 4 weeks removed from surgery or radiation in affected arm~* Primary lymphedema; if edema can be explained by systemic or congenital illnesses, that patient will not be eligible for this study~* Must not have any concurrent condition which in the investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol~* Must not have received any investigational agents within 30 days prior to commencing study treatment~* Active thrombophlebitis~* Pulmonary edema, congestive heart failure or pulmonary embolus

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- recombinant human hyaluronidase (Type: EXPERIMENTAL): Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues